Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 13/20 | 1.00 |
| ▸ | TNFSF11 | O14788 | 11/20 | 1.00 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30645540 | 1.00 | TNF (1.00) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL1270919 | 1.00 | TNF (1.00) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15159836 | 0.90 | TNF (0.81) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL21162208 | 0.89 | TNF (0.80) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15158389 | 0.89 | TNF (0.79) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15832294 | 0.89 | TNF (0.79) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15832298 | 0.88 | TNF (0.78) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL15159837 | 0.87 | TNF (0.76) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL20975834 | 0.85 | TNF (0.74) | TNFTNFSF11TNFRSF1A | |
| SCHEMBL19654771 | 0.85 | TNF (0.74) | TNFTNFSF11TNFRSF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024723-A1 | IL-23 AND TNF-ALPHA INDUCTION TREATMENT FOR AUTOIMMUNE AND INFLAMMATORY DISORDERS | SORRISO PHARMACEUTICALS, INC. (US) | 2025-01-30 | — | — | WO | claimed |
| US-20240094221-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2024-03-21 | — | — | US | claimed |
| EP-4260069-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | Rigshospitalet (DK) | 2023-10-18 | — | — | EP | claimed |
| CN-116829954-A | Method for predicting fertility potential of female subjects | 里格舒斯匹塔里特医院 | 2023-09-29 | — | — | CN | claimed |
| WO-2022122104-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2022-06-16 | — | — | WO | claimed |
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12474348-B2 | Complexes between CD40 and compounds comprising benzimidazole moieties | UCB Biopharma SRL (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250313530-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-08-28 | — | — | US | disclosed |
| CN-119977926-A | Phloroglucinol compound, separation and application in preparation of anti-psoriasis drugs | 华中科技大学 | 2025-05-13 | — | — | CN | disclosed |
| EP-4529468-A1 | FORMULATION OF API'S AND EXCIPIENT'S IN AN ICELL VIA HYDROPHOBIC ION PAIRING | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| EP-4529477-A1 | POROUS EXPANDING BIOCOMPATIBLE SCAFFOLDS | Danmarks Tekniske Universitet (DK) | 2025-04-02 | — | — | EP | disclosed |
| US-20230000861-A1 | TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) SMALL MOLECULE INHIBITOR | AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-115315272-A | Targeting difunctional degradation agent | 耶鲁大学 | 2022-11-08 | — | — | CN | disclosed |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11448655-B2 | Method for identifying a modulator of the TNFα or CD40L interaction with their cognate receptors | UCB Biopharma SRL (BE) | 2022-09-20 | — | — | US | disclosed |
| EP-4041262-A1 | TARGETED BIFUNCTIONAL DEGRADERS | Yale University (US) | 2022-08-17 | — | — | EP | disclosed |
| WO-2022122104-A1 | METHOD FOR PREDICTING THE FERTILITY POTENTIAL OF A FEMALE SUBJECT | RIGSHOSPITALET (DK) | 2022-06-16 | — | — | WO | disclosed |
| WO-2022101453-A1 | COMPOUNDS AND METHODS FOR TREATING A CYTOKINE-MEDIATED DISEASE | Conservatoire National des Arts et Métiers (FR) | 2022-05-19 | — | — | WO | disclosed |
| EP-3960759-A1 | MODULATOR COMPLEX | UCB Biopharma SRL (BE) | 2022-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250269043-A1 | TARGETED BIFUNCTIONAL DEGRADERS | SMURF2, SMURF1, MDM2 | TNF 5/4885TNFSF11 16/4885TNFRSF1A 8/4885 |
| US-12558354-B2 | Tumor necrosis factor alpha (TNF-alpha) small molecule inhibitor | TNF, TNFRSF1A, TNFRSF9 | TNF 1/4885TNFSF11 6/4885TNFRSF1A 2/4885 |
| US-20220339285-A1 | DISSACHARIDE FORMULATIONS FOR CONTROLLED DRUG RELEASE | LIPA, LIPE, CEL | TNF 929/4885TNFSF11 3849/4885TNFRSF1A 3152/4885 |
| US-20230000861-A1 | TUMOR NECROSIS FACTOR ALPHA (TNF-ALPHA) SMALL MOLECULE INHIBITOR | TNF, TNFRSF1A, TNFRSF9 | TNF 1/4885TNFSF11 4/4885TNFRSF1A 2/4885 |
| US-20250313530-A1 | SMALL MOLECULE INHIBITORS OF INTERLEUKIN-4 AND USES THEREOF | IL4, IRAK4, IL5 | TNF 253/4885TNFSF11 62/4885TNFRSF1A 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.